2 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow grapiprant: new trials by email Literature Review of grapiprant trials Research Report on grapiprant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-12-21 | 2025-06-13 |
| Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma grapiprant and pembrolizumab - Non-small Cell Lung Cancer Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Arrys Therapeutics | 18 | 2019-01-08 | 2021-02-21 |
Inflammatory Breast Neoplasms (1)
Arrys Therapeutics (1) · M.D. Anderson Cancer Center (1)
United States (2)
Jason Sager, MD (1) · Sadia Saleem (1)